Prolonged treatment with Tadekinig alfa in adult-onset Still's disease

Ann Rheum Dis. 2020 Jan;79(1):e10. doi: 10.1136/annrheumdis-2018-214496. Epub 2018 Oct 23.

Authors

Uta Kiltz¹, David Kiefer¹, Jürgen Braun¹, Eduardo Jorge Schiffrin², Charlotte Girard-Guyonvarc'h³, Cem Gabay⁴

Affiliations

¹ Rheumazentrum Ruhrgebiet, Herne, Germany.
² AB2 Bio Ltd, Lausanne, Switzerland.
³ Division of Rheumatology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland.
⁴ Division of Rheumatology, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland cem.gabay@hcuge.ch.

PMID: 30352887
DOI: 10.1136/annrheumdis-2018-214496

No abstract available

Keywords: adult onset still's disease; disease activity; treatment.

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Glucocorticoids / therapeutic use
Humans
Immunosuppressive Agents / administration & dosage*
Intercellular Signaling Peptides and Proteins / administration & dosage*
Interleukin-18 / immunology
Male
Methotrexate / therapeutic use
Middle Aged
Recombinant Proteins
Still's Disease, Adult-Onset / drug therapy*
Still's Disease, Adult-Onset / immunology
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Glucocorticoids
Immunosuppressive Agents
Intercellular Signaling Peptides and Proteins
Interleukin-18
Recombinant Proteins
interleukin-18 binding protein
canakinumab
Methotrexate